• Kairos Pharma reported interim Phase 1 safety data for ENV-105 with AstraZeneca’s Tagrisso in EGFR-mutated advanced NSCLC.
• No Grade 3 or higher toxicities tied to ENV-105 were seen in 13 treated patients.
• Clean early safety profile supports continued dose-finding toward a recommended Phase 2 dose.
• Program targets acquired Tagrisso resistance in a market the company estimates at about USD 10 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033289), on July 15, 2026, and is solely responsible for the information contained therein.